| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Kairos Pharma, Ltd.$0.34
+0.02 (+7.26%)
Market Cap
11.67 M
EPS
-0.30
P/E Ratio
-
Value Trade
103.06 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
684.00 K
Operating CF
-1.04 M
Total Assets
5.74 M
Total Liabilities
5.74 M
Equity
5.31 M
D/E Ratio
12,345
13.31 %
Week
-21.01 %
1 Month
-0.91 %
3 Month
-18.18 %
6 Month
-86.38 %
5 Year
-86.38 %
All Time
Cash Data
Cash Position
3.67 M
Monthly Burn
345.00 K
Runway
8.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
43.56 M
52 Week Range
0.40 - 2.11
% held by Insiders
37.2 %
% held by Institutions
2.81 %
Enterprise Value
7.99 M
Total Shares
21.41 M
Short %
1.16 %
Float Shares
13.45 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kairos Pharma, Ltd.
41Total events
0Upcoming
13Tier-1 (high impact)
2024 – 2026Coverage
Event history 2
TBD
◆Safety Data UpdateENV-105Clinical Data
Subscribe to view catalyst details
TBD
◆Topline ReadoutENV-105Clinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ENV-105 | advanced metastatic prostate cancer | Phase 2 | 2025-12-17 | 86%; four months; beyond one year | Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer Read More | |
ENV-105 | advanced metastatic prostate cancer | Phase 2 | 2025-12-17 | 86%; four months; beyond one year | Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer Read More | |
ENV-105 | advanced metastatic prostate cancer | Phase 2 | 2025-12-17 | 86%; four months; beyond one year | Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KAPA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KAPA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KAPA▼ -6.5%on this news
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Kairos Pharma has announced promising interim safety data from its Phase 1 trial of ENV-105, a treatment for advanced EGFR-mutated non-small cell lung cancer. The trial evaluates ENV-105 in combination with osimertinib, aiming to address drug resistance in cancer patients. This milestone highlights the potential of ENV-105 in a lucrative market.
Read more →KAPAKairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Kairos Pharma Ltd. provided a mid-year update for 2026, highlighting its acquisition of CL-741, a promising oncology asset targeted for non-small cell lung cancer. The company plans to leverage its expertise in drug resistance therapeutics to advance its pipeline, with several key clinical milestones expected in the coming months. Financially, Kairos maintains a robust position with over $8 million secured in non-dilutive funding. However, the company acknowledges inherent risks related to clinical trials and regulatory approvals that could impact anticipated outcomes.
Read more →KAPAKairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Kairos Pharma has signed binding terms to acquire CL-273 from Celyn Therapeutics, aiming to enhance its pipeline for EGFR-mutant lung cancer therapies. This investigational drug is designed to target resistant mutations and is backed by significant investment. The acquisition is expected to position Kairos Pharma strongly in a lucrative market projected to reach $16.2 billion by 2026.
Read more →KAPA▼ -12.2%on this newsshared move
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma, Ltd. has signed a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, focusing on non-small cell lung cancer (NSCLC). The assets include CL-273, a pan-EGFR inhibitor, and CL-741, a c-MET kinase inhibitor. This acquisition aims to enhance Kairos's oncology pipeline and address significant unmet medical needs in cancer treatment. The company plans to leverage its clinical infrastructure to expedite development.
Read more →KAPAKairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Kairos Pharma Ltd. will present at the DealFlow Discovery Conference on January 28-29, 2026, in Atlantic City, NJ. Chief Scientific Officer Neil Bhowmick will deliver a presentation and hold one-on-one investor meetings. The company is advancing its lead candidate, ENV-105, which targets CD105 to combat drug resistance in cancer therapies.
Read more →KAPAKairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Kairos Pharma Ltd. has been awarded the 2025 Clinical Trials Arena Excellence Award for its innovative work in advanced prostate cancer. The award recognizes the development of ENV-105, a monoclonal antibody targeting CD105, which has shown promising interim results in a Phase 2 trial. The therapy aims to restore sensitivity to hormone treatments in patients with metastatic castration-resistant prostate cancer.
Read more →KAPAKairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 Los Angeles, CA
Kairos Pharma, a clinical-stage biopharmaceutical company, will present positive safety and efficacy data from a Phase 2 trial focusing on advanced, castration-resistant prostate cancer at the ESMO Congress in Berlin. The study evaluates the combination of apalutamide and carotuximab in men who have shown resistance to previous hormone therapies. This trial is particularly relevant as metastatic castration-resistant prostate cancer poses significant challenges in treatment, highlighting the potential effectiveness of Kairos’s investigational therapy. The presentation is scheduled for October 17-21, 2025.
Read more →KAPA▼ -20.2%on this news· ran to -32% by day 3
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year Interim efficacy analysis highlights potential valu
Kairos Pharma has announced positive interim efficacy data from its Phase 2 trial of ENV105 for advanced prostate cancer, demonstrating a median progression-free survival of over 13 months. The trial utilized a combination of ENV105 and the hormone therapy apalutamide, highlighting the drug's potential in treating metastatic castration-resistant prostate cancer. The study, which aims to enroll 100 patients, noted that the treatment was well tolerated without severe toxicities. A virtual KOL discussion will be hosted to further analyze this data.
Read more →KAPAKairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer Event to feature principal investigators from the trial
Kairos Pharma, a clinical-stage biopharmaceutical company, announced a virtual KOL event to discuss interim efficacy results of ENV105 in a Phase 2 trial for advanced prostate cancer. Scheduled for September 18th, the event will feature insights from principal investigators. Positive interim safety results show that ENV105 is well tolerated in combination with apalutamide, highlighting its potential role in addressing drug resistance in cancer therapy. This development aims to provide a safe alternative for patients facing castration-resistant prostate cancer.
Read more →KAPAKairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
Kairos Pharma, Ltd. has announced the presentation of initial Phase 1 data on its drug ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer. The presentation is scheduled for the World Lung Cancer Conference taking place from September 6-9, 2025, in Barcelona, Spain. The open-label trial primarily aims to evaluate the safety and tolerability of this combination therapy. ENV105 targets CD105, a protein implicated in drug resistance, addressing significant unmet needs in cancer treatment. The company continues to pursue additional trials to validate the efficacy of this novel approach.
Read more →KAPA▲ +70.8%on this news
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive safety results from the ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The interim analysis showed that the treatment was well tolerated alongside standard hormone therapy, with no significant adverse events reported. The study, which aims to enroll a total of 100 patients, is being conducted at several medical centers and aims to evaluate the safety, tolerability, and early efficacy signs of ENV-105. Further efficacy data is expected in September 2025, and Kairos plans to engage with regulatory agencies for potential Phase 3 study design discussions.
Read more →KAPA▲ +19.8%on this news
Dr. John Yu, Chief Executive Officer Kairos Pharma, Ltd. 2355 Westwood Boulevard - Suite 139 Los Angeles, CA 90064
Kairos Pharma, Ltd. has entered into a services agreement with Barretto Pacific Corporation to enhance its investor relations and public presence. The agreement, effective June 10, 2025, outlines a range of services including communication with the investment community, organization of conference calls, and assistance with research reports. This partnership aims to improve the company's engagement with potential investors. However, the agreement comes with a significant financial commitment of $170,000 over the contract's duration.
Read more →KAPA▼ -23.5%on this news
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Kairos Pharma Ltd. has announced promising new data on KROS 101, an investigational small molecule GITR ligand agonist, presented at the ASCO 2025 Annual Meeting. The findings indicate that KROS 101 enhances T cell function and boosts immune response against cancer, showing significant advantages over existing treatments. With a dual mechanism of action, the study suggests that KROS 101 may effectively improve therapeutic outcomes for cancer patients, addressing critical unmet medical needs. Kairos Pharma's CEO emphasized that these results bolster the potential for KROS 101 to optimize cancer treatment strategies.
Read more →KAPAKairos Pharma Ltd. Provides Letter to Stockholders
Kairos Pharma Ltd. announced an update to stockholders reflecting on the company's advancements since its public offering. The letter highlighted the ongoing Phase 1 and Phase 2 clinical trials for the lead drug ENV105, aimed at treating prostate and lung cancer. They reported financial stability bolstered by non-dilutive grants and partnerships while discussing the potential impacts of recent economic headwinds. The company is also developing other immune response compounds and maintaining strong research analyst coverage.
Read more →KAPAKairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
Kairos Pharma Ltd. has announced a significant breakthrough in overcoming drug resistance in non-small cell lung cancer (NSCLC) through a peer-reviewed publication. The study highlights the role of CD105 in mediating resistance to osimertinib, revealing that targeting this molecule with ENV105 can restore treatment sensitivity. These findings support the potential of ENV105 as a high-value asset in oncology and may represent a paradigm shift in the treatment of cancers resistant to current therapies. With ongoing clinical trials, Kairos is positioned to address critical unmet medical needs in lung cancer treatment.
Read more →KAPA▲ +8.8%on this news
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma
Kairos Pharma presented promising preclinical data on its investigational compounds KROS 101 and KROS 401 at the AACR IO conference. KROS 101, a GITR agonist, showed significant inhibition of tumor growth in melanoma models and enhanced T cell activity. Meanwhile, KROS 401 demonstrated potential in reprogramming macrophages to inhibit tumor growth in glioma animal models. These findings suggest both compounds could be valuable therapeutics for melanoma and glioblastoma.
Read more →KAPA▼ -8.9%on this news
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13 th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma
Kairos Pharma presented promising data on its investigational compound, KROS 101, at the 13th AACR-JCA Joint Conference. The data demonstrate KROS 101's potential to enhance anti-tumor T cell responses and reprogram the tumor microenvironment in melanoma and glioblastoma. Preclinical findings indicated significant T cell proliferation and tumor reduction. The company's executives emphasized the potential of KROS 101 as a novel therapy for cancer, particularly in exploiting GITR as a target for T cell expansion.
Read more →KAPA▼ -14%on this news
Kairos Pharma Approved to Dual List on Upstream Trading to begin
Kairos Pharma, Ltd. (KAPA) has received approval to dual list its shares on the Upstream market, set to commence on November 26, 2024. This move aims to provide the company access to a broader global investor base, thereby enhancing liquidity and price discovery. John Yu, the CEO, emphasized that this strategic decision aligns with the company's goal to build shareholder value while advancing their lead drug, ENV105, through clinical trials for various cancers.
Read more →KAPA▼ -14%on this news
Kairos Pharma Approved to Dual List on Upstream
Kairos Pharma, Ltd. (KAPA) has received approval for a dual listing on Upstream, a global securities trading app, which will be effective from November 26, 2024. This move aims to provide access to a broader investor base outside of the U.S., enhancing liquidity and price discovery. The dual listing is expected to complement Kairos Pharma's ongoing development of its lead drug ENV105, aimed at treating various cancers. The trading environment on Upstream features real-time trading and a transparent orderbook.
Read more →KAPAKairos Pharma to Present at the LD Micro Main Event XVII
Kairos Pharma Ltd. is set to present a corporate overview at the LD Micro Main Event XVII, taking place from October 28 to 30, 2024, in Los Angeles. The presentation will focus on the company's lead candidate, ENV105, which targets CD105 and aims to reverse drug resistance in cancer treatments. Currently, ENV105 is in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. This event offers an important platform for Kairos Pharma to enhance its visibility and communicate its mission to investors.
Read more →KAPAKairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Kairos Pharma Ltd. announced that CEO John S. Yu will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024. The summit will focus on advancing discussions in biotechnology and oncology therapeutics. During the event, Yu is expected to discuss Kairos's lead candidate, ENV105, which targets CD105 to combat cancer drug resistance. This chat presents an opportunity for the company to engage with investors and industry stakeholders about their ongoing clinical trials and innovative strategies.
Read more →KAPAKairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
Kairos Pharma Ltd. has entered into a partnership with PreCheck Health Services to develop biomarkers that identify patients responsive to ENV105, a new therapy aimed at treating drug-resistant prostate and lung cancers. This strategic agreement is aimed at enhancing patient screening and therapy monitoring during Kairos Pharma's clinical trials. The collaboration will utilize advanced genetic sequencing and molecular diagnostics to confirm existing biomarkers while exploring new ones to predict patient responses to ENV105. This initiative represents a significant step towards achieving personalized cancer treatment and improving patient outcomes.
Read more →KAPA▼ -5.4%on this news· ran to -16% by day 3
Kairos Pharma Closing of $6.2 Million Initial Public Offering
Kairos Pharma, a clinical-stage biopharmaceutical company, has closed its initial public offering of 1,550,000 shares at $4.00 per share, raising a total of $6.2 million. The funds will support ongoing clinical trials for its lead cancer drug candidate ENV 105, aimed at reversing drug resistance and immune suppression in cancer patients. Additionally, the company will advance other preclinical candidates. Trading on the NYSE American began on September 16, 2024.
Read more →KAPAKairos Pharma Prices $6.2 Million Initial Public Offering
Kairos Pharma, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) at $4.00 per share, aiming to raise $6.2 million. The offering involves 1,550,000 shares, with the potential for an additional 232,500 shares to be purchased by underwriters. Proceeds will fund clinical trials for the Company’s lead product, ENV 105, which aims to combat cancer drug resistance. Trading is expected to commence on September 16, 2024, under the ticker symbol 'KAPA'.
Read more →KAPAKairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
Kairos Pharma has initiated its Phase 2 trial by dosing the first patient with its lead candidate ENV105 in combination with apalutamide, targeting castrate-resistant prostate cancer (CRPC). This trial aims to evaluate the efficacy of the combination therapy in patients who have developed resistance to androgen signaling inhibitors. Previous studies indicated that ENV105 could convert 44% of CRPC patients to castrate sensitivity, highlighting its potential in improving treatment options for this challenging condition. The multi-site trial plans to enroll 100 patients and is part of Kairos Pharma's broader efforts to develop innovative cancer therapeutics.
Read more →KAPAKairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer
Kairos Pharma has initiated a Phase 1 trial for its lead drug candidate, ENV105, in combination with osimertinib for non-small cell lung cancer treatment. This trial, which has dosed its first two patients, aims to evaluate the safety and tolerability of this combination therapy. ENV105 is designed to enhance the sensitivity of patients who have developed resistance to osimertinib, addressing a critical challenge in treating EGFR-driven lung cancer. The trial plans to enroll 60 patients experiencing resistance or partial sensitivity to standard treatments.
Read more →Competitive Position
How KAPA ranks across every disease it competes inCompetitive Position is a premium feature
See how KAPA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial